figshare
Browse
13075_2021_2709_MOESM4_ESM.pptx (140.52 kB)

Additional file 4 of Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models

Download (140.52 kB)
presentation
posted on 2022-01-06, 04:29 authored by Cindy Orvain, Anne Cauvet, Alexis Prudent, Christophe Guignabert, Raphaël Thuillet, Mina Ottaviani, Ly Tu, Fanny Duhalde, Carole Nicco, Frédéric Batteux, Jérôme Avouac, NingXin Wang, Michelle A. Seaberg, Stacey R. Dillon, Yannick Allanore
Additional file 4: Supplementary Figure 3. Gating strategy of T cell sub-populations and activation markers in Fra-2 Tg spleen. Spleen CD3+ T cells were selected in live-gated populations. From total live CD3+ T cells, CD4+ and CD8+ populations were selected. PD-1 (1) and CD69 (2) expression were analysed in CD4+ and CD8+ populations. Among CD4+ or CD8+ T cells, TCM (CD62L+ CD44+, in blue), TEM (CD44+ CD62L-, in purple) and naïve T (CD62L+ CD44-, in green) were selected (3).

Funding

Alpine Immune Sciences

History

Usage metrics

    Arthritis Research & Therapy

    Categories

    Keywords

    Systemic sclerosisDermal fibrosisPulmonary fibrosisPulmonary hypertensionCostimulation blockadeICOSCD28

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC